Kodiak Sciences Inc. (KOD)

Market Cap	284.29M
Revenue (ttm)	n/a
Net Income (ttm)	-356.54M
Shares Out	54.25M
EPS (ttm)	-6.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	354,005
Open	5.15
Previous Close	5.03
Day's Range	4.97 - 5.38
52-Week Range	4.90 - 12.80
Beta	1.79
Analysts	Buy
Price Target	12.37 (+136.52%)
Earnings Date	Mar 21, 2023

About KOD

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate include...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 4, 2018
• Employees: 105
• Stock Exchange: NASDAQ
• Ticker Symbol: KOD

Analyst Forecast

According to 14 analysts, the average rating for KOD stock is "Buy." The 12-month stock price forecast is $12.37, which is an increase of 136.52% from the latest price.

Price Target

$12.37

(136.52% upside)

Analyst Consensus: Buy